| Dr John Philip Clark, PHARMD | |
|
270 Copperfield Blvd Ne, Suite 101, Concord, NC 28025-2441 | |
| (704) 784-9613 | |
| (704) 789-9366 |
| Full Name | Dr John Philip Clark |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 270 Copperfield Blvd Ne, Concord, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083720924 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 18440 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Philip Clark, PHARMD 270 Copperfield Blvd Ne, Suite 101, Concord, NC 28025-2441 Ph: (704) 784-9613 | Dr John Philip Clark, PHARMD 270 Copperfield Blvd Ne, Suite 101, Concord, NC 28025-2441 Ph: (704) 784-9613 |
News Archive
New research shows that a surgical procedure using a cutting-edge super glue pioneered a year ago by Calgary researchers can improve the recovery of heart patients recovering from open-chest surgery, Dr. Paul Fedak today told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug Application for dasotraline, a novel dual-acting dopamine and norepinephrine reuptake inhibitor, for the treatment of attention-deficit hyperactivity disorder.
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Platinum complexes such as the well-known cisplatin are powerful antitumor medications. They cross the cell membrane and reach the nucleus, where they attach to DNA and stop cell growth. But how does cisplatin get to the nucleus Italian researchers have now proven that a copper transport protein may play a critical role.
Researchers from the Molecular Cancer group at the Hospital del Mar Medical Research Institute and doctors from Hospital del Mar, have demonstrated the effectiveness of a drug for treating metastatic bladder cancer in patients who did not respond to the usual treatment.
› Verified 2 days ago
Christina Maneen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 44 Branchview Dr Ne, Concord, NC 28025 Phone: 704-788-3162 | |
Kiera Emery, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1111 Old Charlotte Rd, Concord, NC 28027 Phone: 706-955-9100 | |
Kathryn Cortney Hudgens Christenson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10 Pitts School Rd Sw, Concord, NC 28027 Phone: 704-795-0091 Fax: 704-795-0106 | |
Dr. Shannon Elizabeth Rudolph, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 270 Copperfield Blvd Ne, Suite 101, Concord, NC 28025 Phone: 704-784-9613 | |
Jessica Patricia Cole, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 920 Church St N, Concord, NC 28025 Phone: 412-526-0545 | |
Heather Nguyen, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 807 Davidson Dr Nw, Concord, NC 28025 Phone: 704-786-0135 | |
Dr. Justin Boyer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1560 Highway 29 N, Concord, NC 28025 Phone: 704-786-5157 |